Evofem Biosciences to Report First Quarter 2021 Results and Provide Corporate Update on Thursday, May 6, 2021
04/22/2021 - 08:00 AM
SAN DIEGO , April 22, 2021 /PRNewswire/ -- Evofem Biosciences, Inc., (NASDAQ: EVFM) will hold a webcast and conference call to discuss the Company's financial results and business highlights for the first quarter ended March 31, 2021 as follows:
Date
Thursday, May 6, 2021
Time
4:30 p.m. ET (1:30 p.m. PT)
Webcast (live and archived)
www.evofem.com under "Investors "
Dial-in numbers
(866) 503-5561 (U.S. toll-free) or (253) 336-2965
Conference ID
1899453
The live webcast and related slide presentation can be accessed through the Investors section of its website or directly at https://evofem.investorroom.com/2021Q1Results . Please connect to the Company's website at least 15 minutes prior to the start of the call to download any software that may be required. If participating by phone, please dial in approximately 15 minutes prior to the start of the call.
The webcast will be archived at https://evofem.investorroom.com/2021Q1Results . A telephone replay will be available for 24 hours after the call at (855) 859-2056 (U.S.) or (404) 537-3406 (International), conference ID 1899453.
About Evofem Biosciences Evofem Biosciences, Inc., (NASDAQ: EVFM) is a commercial-stage biopharmaceutical company committed to developing and commercializing innovative products to address unmet needs in women's sexual and reproductive health, including hormone-free, woman-controlled contraception and protection from certain sexually transmitted infections (STIs). The Company launched its first FDA-approved commercial product, Phexxi® contraceptive vaginal gel, in the United States in September 2020. Evofem's lead product candidate, EVO100, is being evaluated for the prevention of urogenital Chlamydia trachomatis and Neisseria gonorrhoeae infection in women in the ongoing Phase 3 clinical trial, 'EVOGUARD .' For more information, please visit evofem.com .
Phexxi® is a registered trademark of Evofem Biosciences, Inc.
Investor Relations Contact Amy Raskopf araskopf@evofem.com
http://www.prnewswire.com/news-releases/evofem-biosciences-to-report-first-quarter-2021-results-and-provide-corporate-update-on-thursday-may-6-2021-301274348.html
SOURCE Evofem Biosciences, Inc.
EVFM Rankings
N/A Ranked by Stock Gains
EVFM Stock Data
Industry
Pharmaceutical Preparation Manufacturing
Sector
Manufacturing
Tags
Health Technology, Biotechnology, Manufacturing, Pharmaceutical Preparation Manufacturing
Country
US
City
San Diego
About EVFM
evofem is a biotechnology company focusing on developing innovative reproductive health products for women in every global market. evofem develops and markets products that are woman-controlled, non-invasive and rapidly reversible. women need access to effective products that are well suited to their lifestyle and consistent with their core values. products include: amphora™ - a non-hormonal vaginal gel being investigated for contraceptive and microbicidal properties.
